Recorded Chinese product: 复方电解质葡萄糖注射液-M3A复方电解质葡萄糖注射液-M3A
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 四川科伦药业股份有限公司Chinese legal name: 四川科伦药业股份有限公司
主要成分Active Ingredients
- 氯化钾Lvhua Jia
- 葡萄糖Putao Tang
药物知识说明
氯化钾是一种在国家药监局注册认定的药品。该药品含有氯化钾、葡萄糖-31b6cd73等成分。
该药品关联的活性成分包括：氯化钾Lvhua Jia、葡萄糖Putao Tang。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：四川科伦药业股份有限公司Chinese legal name: 四川科伦药业股份有限公司。
您可以探索含有相同成分的其他药品：氯化钾-35118289成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 复方电解质葡萄糖注射液-M3A) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 氯化钾Lvhua Jia, 葡萄糖Putao Tang.
Manufacturers recorded for this product: 四川科伦药业股份有限公司Chinese legal name: 四川科伦药业股份有限公司.
Explore other medicines containing the same ingredient: 氯化钾 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 复方电解质葡萄糖注射液-M3ARecorded Chinese product: 复方电解质葡萄糖注射液-M3A
- 规格Specification: 500ml500 mL
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 四川科伦药业股份有限公司Chinese legal name: 四川科伦药业股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20064892
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20064892
Manufacturer
Chinese legal name: 四川科伦药业股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20064892
生产企业
四川科伦药业股份有限公司(国产)
适应症
体液与电解质补充药。在经口摄取不可能或不充分时，补充并维持水分和电解质。
用法用量
成人，一次500ml～1000ml静脉点滴。给药速度，成人为每小时300ml～500ml（每分钟约80～130滴）；小儿每小时50ml～100ml，并按年龄、症状、体重适当增减。
不良反应
急速大量给药时，有可能出现肺水肿、脑水肿、末梢水肿、水中毒以及高钾血症。
禁忌
1? 高乳酸血症；2? 高钾血症、少尿、阿狄森病、重症烧伤、高氮质血症患者；3? 不伴有高钾血症的肾功能不全患者；4? 心功能不全患者；5? 严重肝功能不全患者；6? 因阻塞性尿路疾患而引起尿量减少的患者；7? 糖尿病患者。
注意事项
最好在患者尿量为一日500ml或每小时20ml以上时使用本品。
贮藏
密闭保存。
规格
500ml
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.